Literature DB >> 18722558

Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention.

Wan-Uk Kim1, Antoine Sreih, Richard Bucala.   

Abstract

Recent experimental and clinical studies have placed new emphasis on the role of the innate immune system in SLE. Nucleic acid-containing immune complexes activate the innate response by engaging specific Toll-like receptors (TLRs) and promote the generation of autoantibodies. Pharmacologic modulation of TLR-directed pathways may offer new therapeutic approaches for the treatment of SLE.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18722558      PMCID： PMC2654252          DOI： 10.1016/j.autrev.2008.07.046

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN： 1568-9972            Impact factor:   9.754


  40 in total

Review 1.  Oxidative DNA damage: mechanisms, mutation, and disease.

Authors:  Marcus S Cooke; Mark D Evans; Miral Dizdaroglu; Joseph Lunec
Journal:  FASEB J       Date:  2003-07       Impact factor: 5.191

2.  DNA and RNA autoantigens as autoadjuvants.

Authors:  Liliana Busconi; Christina M Lau; Abigail S Tabor; Melissa B Uccellini; Zachary Ruhe; Shizuo Akira; Gregory A Viglianti; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  J Endotoxin Res       Date:  2006

3.  Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

Authors:  P Blanco; A K Palucka; M Gill; V Pascual; J Banchereau
Journal:  Science       Date:  2001-11-16       Impact factor: 47.728

4.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

5.  Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides.

Authors:  R A Zeuner; D M Klinman; G Illei; C Yarboro; K J Ishii; M Gursel; D Verthelyi
Journal:  Rheumatology (Oxford)       Date:  2003-04       Impact factor: 7.580

Review 6.  TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity.

Authors:  Roberto Baccala; Kasper Hoebe; Dwight H Kono; Bruce Beutler; Argyrios N Theofilopoulos
Journal:  Nat Med       Date:  2007-05       Impact factor: 53.440

7.  DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice.

Authors:  Z K Wen; W Xu; L Xu; Q H Cao; Y Wang; Y W Chu; S D Xiong
Journal:  Rheumatology (Oxford)       Date:  2007-12       Impact factor: 7.580

Review 8.  DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients.

Authors:  Ying Zhou; Qianjin Lu
Journal:  Autoimmun Rev       Date:  2008-04-04       Impact factor: 9.754

Review 9.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 10.  A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus.

Authors:  L Rönnblom; G V Alm
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307
View more
  31 in total

Review 1.  IRF7: activation, regulation, modification and function.

Authors:  S Ning; J S Pagano; G N Barber
Journal:  Genes Immun       Date:  2011-04-14       Impact factor: 2.676

2.  Infection in systemic lupus erythematosus: friend or foe?

Authors:  Lisa Francis; Andras Perl
Journal:  Int J Clin Rheumtol       Date:  2010-02-01

Review 3.  Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases.

Authors:  Jing Li; Xiaohui Wang; Fengchun Zhang; Hang Yin
Journal:  Pharmacol Ther       Date:  2013-03-24       Impact factor: 12.310

Review 4.  Exploring the etiopathogenesis of systemic lupus erythematosus: a genetic perspective.

Authors:  Ali Javinani; Amir Ashraf-Ganjouei; Saeed Aslani; Ahmadreza Jamshidi; Mahdi Mahmoudi
Journal:  Immunogenetics       Date:  2019-01-22       Impact factor: 2.846

5.  Toll-like receptors are potential therapeutic targets in rheumatoid arthritis.

Authors:  Siamak Sandoghchian Shotorbani; Zhao-Liang Su; Hua-Xi Xu
Journal:  World J Biol Chem       Date:  2011-07-26

6.  Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus.

Authors:  Antoine Sreih; Rana Ezzeddine; Lin Leng; Avery LaChance; Geraldine Yu; Yuka Mizue; Lakshman Subrahmanyan; Bernardo A Pons-Estel; Anna-Karin Abelson; Iva Gunnarsson; Elisabet Svenungsson; Joshua Cavett; Stuart Glenn; Lin Zhang; Ruth Montgomery; Andras Perl; Jane Salmon; Marta E Alarcón-Riquelme; John B Harley; Richard Bucala
Journal:  Arthritis Rheum       Date:  2011-12

7.  Differential responses to Smith D autoantigen by mice with HLA-DR and HLA-DQ transgenes: dominant responses by HLA-DR3 transgenic mice with diversification of autoantibodies to small nuclear ribonucleoprotein, double-stranded DNA, and nuclear antigens.

Authors:  Chao Jiang; Umesh S Deshmukh; Felicia Gaskin; Harini Bagavant; Julie Hanson; Chella S David; Shu Man Fu
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

8.  Belimumab in systemic lupus erythematosus: an update for clinicians.

Authors:  Susan S Kim; Kyriakos A Kirou; Doruk Erkan
Journal:  Ther Adv Chronic Dis       Date:  2012-01       Impact factor: 5.091

Review 9.  Toll-like receptors: potential targets for lupus treatment.

Authors:  Yan-wei Wu; Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

10.  Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus.

Authors:  C K Wong; P T Y Wong; L S Tam; E K Li; D P Chen; C W K Lam
Journal:  Clin Exp Immunol       Date:  2009-10-16       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.